Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.03
<$0.01(19.29%)
At close: 4:00 PM EDT
$0.03
<$0.01(19.29%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume458.46K
Average Volume (3M)410.07K
Market Cap
$14.87M
Enterprise Value$33.45
Total Cash (Recent Filing)$186.01B
Total Debt (Recent Filing)$16.16T
Price to Earnings (P/E)<0.1
Beta-0.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding457,512,800
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate Recent LeverageModerate recent leverage provides some solvency support and may reduce immediate balance-sheet pressure. However, historical periods of materially higher leverage and volatile returns indicate that this strength is not yet consistently established.
Near-Term Funding AccessAccess to convertible financing gives the company near-term liquidity to continue operations and development activities. This supports business continuity, although the funding structure remains costly and creates dilution risk for existing shareholders.
Performance-Based IncentivesThe conditional RSU structure links employee and executive rewards to a potential national-exchange uplisting and retention. This may improve management alignment with longer-term corporate objectives, though the awards are contingent and potentially dilutive.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow shows that the business is not self-funding. Continued cash burn increases dependence on external capital, constrains investment flexibility, and makes durable value creation reliant on successful development outcomes.
Pre-Revenue Operating ModelVery limited and inconsistent revenue, combined with recurring operating losses, indicates a high-risk pre-revenue biotech model. Earnings visibility is weak, and the company lacks an established commercial base to support development spending over the medium term.
Convertible Financing DilutionDiscounted variable-price conversion terms and commitment shares can materially dilute existing holders. The one-year maturity, high interest rate, and default provisions also show financing dependence and may limit strategic flexibility if operating cash generation remains weak.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $14.87M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Oncotelic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 457,512,800 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.